News
ABOS
1.630
-1.21%
-0.020
Weekly Report: what happened at ABOS last week (0113-0117)?
Weekly Report · 2d ago
Weekly Report: what happened at ABOS last week (0106-0110)?
Weekly Report · 01/13 09:08
Acumen announces Phase 1 INTERCEPT-AD study publication
TipRanks · 01/09 13:05
Insider Sale: Chief Executive Officer of $ABOS (ABOS) Sells 47,778 Shares
NASDAQ · 01/08 01:15
Insider Sale: Chief Legal Officer & Corp Sec of $ABOS (ABOS) Sells 11,122 Shares
NASDAQ · 01/08 01:01
Analysts Offer Insights on Healthcare Companies: Acumen Pharmaceuticals (ABOS) and Immix Biopharma, Inc. (IMMX)
TipRanks · 01/06 11:30
Weekly Report: what happened at ABOS last week (1230-0103)?
Weekly Report · 01/06 09:08
Weekly Report: what happened at ABOS last week (1223-1227)?
Weekly Report · 12/30/2024 09:08
Weekly Report: what happened at ABOS last week (1216-1220)?
Weekly Report · 12/23/2024 09:08
Weekly Report: what happened at ABOS last week (1209-1213)?
Weekly Report · 12/16/2024 09:09
Weekly Report: what happened at ABOS last week (1202-1206)?
Weekly Report · 12/09/2024 09:08
Weekly Report: what happened at ABOS last week (1125-1129)?
Weekly Report · 12/02/2024 09:08
Weekly Report: what happened at ABOS last week (1118-1122)?
Weekly Report · 11/25/2024 09:08
Weekly Report: what happened at ABOS last week (1111-1115)?
Weekly Report · 11/18/2024 09:07
ACUMEN PHARMACEUTICALS INC <ABOS.O>: BOFA GLOBAL RESEARCH CUTS PRICE OBJECTIVE TO $12 FROM $14
Reuters · 11/13/2024 15:14
Bank of America Securities Keeps Their Buy Rating on Acumen Pharmaceuticals (ABOS)
TipRanks · 11/13/2024 14:56
Acumen Pharmaceuticals Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones · 11/13/2024 14:47
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga · 11/13/2024 14:37
Acumen Pharmaceuticals: A Promising Contender in Alzheimer’s Treatment with Targeted Oligomeric Abeta Approach
TipRanks · 11/13/2024 11:35
Acumen Pharmaceuticals, Inc. Reports Quarterly Results for the Period Ended September 30, 2024
Press release · 11/13/2024 04:45
More
Webull provides a variety of real-time ABOS stock news. You can receive the latest news about Acumen Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ABOS
More
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in clinical development following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to Alzheimer’s pathology). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The Company is developing sabirnetug for intravenous (IV), administration every four weeks for the treatment of early AD.